AB Science Completes EUR 1.925 Million Private Placement

AB Science S.A. has announced the successful completion of a EUR 1.925 million private placement. The transaction was achieved through the issuance of 1,645,302 new ordinary shares, each with an attached share warrant. The company aims to use the proceeds primarily for the clinical development of the AB8939 program. This transaction enhances the company's cash position, addressing financing needs for 2025 and beyond.

A total of 1,645,302 new shares were issued, representing 2.47% of the company's pre-placement share capital and 2.41% post-placement. Each pair of share and warrant is priced at EUR 1.17, reflecting a 24.36% discount to the recent market average. If all warrants are exercised, they could yield an additional EUR 2.93 million.

The new shares will start trading on Euronext Paris on July 10, 2025. AB Science's recent actions indicate a strategic focus on strengthening their financial structure to further support crucial research and development activities.